Statistics

Total Visits

Views
Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors15

Select a period of time:

Number of views in the range

Views
Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors9

Views

Views
May 20242
June 20243
July 20240
August 20242
September 20241
October 20240
November 20241
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States6
United Kingdom3
 

Top cities views

Views
Ashburn1
Chicago1